Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

COVID-19, diabetes mellitus and ACE2: The conundrum

Open access
Pal, Rimesh, Bhansali, Anil·2020·Diabetes Research and Clinical Practice

Abstract

2020 Elsevier B.V. All rights reserved. A novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has scourged the world since its outbreak in December 2019 at Wuhan, China resulting in the World Health Organization declaring it as a pandemic. As of March 22, 2020, COVID-19 has affectedover292,000people in at least 185 countriesworldwidewithmost of the cases being reported fromChina, Europe and the United States of America. The absolute number of deaths has already surpassed 12,750 globally and is expected to increase further as the disease spreads rapidly. The disease has also infiltrated the Indian masses and is spreading fast. India being a developing nationwithmore than 1.3 billion people, failure to contain the virus can lead to disastrous consequences with death toll perhaps surpassing all other nations. Although the overall mortality rate of COVID-19 is low (1.4– 2.3%), patients with comorbidities are more likely to have severe disease and subsequent mortality [1,2]. Most of the available studies have shown that diabetes mellitus (DM) as a distinctive comorbidity is associated with more severe disease, acute respiratory distress syndrome and increased mortality [1,3,4]. Amongst the 32 non-survivors from a group of 52 intensive care unit (ICU) patients, DM (22%) was a predominant underlying comorbidity [3]. Of the 1099 confirmed COVID-19 patients reported by Guan et al. from China, 173 had severe disease; patients with severe disease had a higher prevalence of DM (16.2%) as compared to those with non-severe disease (5.7%) [1]. Further, in the largest series reported by the Chinese Center for Disease Control and Prevention comprising of 72,314 cases of COVID-19, patients with DM had higher mortality (7.3% in DM vs. 2.3% overall) [2]. It can be assumed that patients with DM are more likely to be older than thosewithout DM and advancing age has consistently been shown to be associated with poor prognosis in COVID-19, however, most of the aforementioned studies did not adjust for age. Nevertheless, diabetes has been uniformly reported to be associated with poor prognosis in other viral infections, notably seasonal influenza, pandemic influenza A H1N1 (2009), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) [5–8]. Multiple explanations can be put forward for this apparent association between pre-existing DM and COVID-19 severity. Innate immunity, the first line of defense against SARS-CoV-2, is inevitably compromised in patients with uncontrolled DM thereby allowing unhindered proliferation of the pathogen within the host [9]. Even short-term hyperglycemia has been shown to transiently stun the innate immune system [10]. Moreover, DM is characterized by exaggerated pro-inflammatory cytokine response, notably interleukin (IL)-1, IL-6 and

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2020.108132

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 349

Metadata

Authors
Pal, R., & Bhansali, A.
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2020-04
Volume
162
Pages
108132
ISSN
0168-8227 (ISSN-L)
OpenAlex
W3013894664
Cited by
349
References
15
FWCI
9.78
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19, diabetes mellitus and ACE2: The conundrum. https://app.cochat.ai/papers/10.1016/j.diabres.2020.108132
The paper
Pal, R., & Bhansali, A. (2020). COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2020.108132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.